Rotavirus Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Rotavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus be contracted from inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms include severe diarrhea, vomiting, fever, and dehydration.
The Rotavirus Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Rotavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Rotavirus Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 29 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Rotavirus Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Rotavirus Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Rotavirus Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aridis Pharmaceuticals IncBeijing Minhai Biotechnology Co Ltd
Bharat Biotech Ltd
Blue Water Biotech Inc
Butantan Institute
Chain Biotechnology Ltd
Chongqing Zhifei Biological Products Co Ltd
ConserV Bioscience Ltd
Curevac NV
GSK plc
Hilleman Laboratories Pvt Ltd
IGY Immune Technologies & Life Sciences Inc
Institute of Medical Biology Chinese Academy of Medical Sciences
International Vaccine Institute
Inventprise LLC
MAXVAX Biotechnology Co Ltd
Micron Biomedical Inc
Murdoch Childrens Research Institute
PATH
Serum Institute of India Pvt Ltd
Sinovac Biotech Ltd
SK Bioscience Ltd
Symvivo Inc
The Gamaleya National Center of Epidemiology and Microbiology
Vanderbilt University
Wuhan Institute of Biological Products Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Rotavirus Infections reports